Improving Vaccine Assessment Pathways and Decision Making in the Polish Immunization Program.

Poland decision making health technology assessment immunization policies medicines policy national immunization technical advisory groups vaccine assessment

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
09 Mar 2024
Historique:
received: 16 01 2024
revised: 23 02 2024
accepted: 28 02 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

This study examines the vaccine market access pathway in Poland to evaluate its efficiency and propose recommendations for its improvement. The research spans a comprehensive analysis of the vaccine assessment process, ranging from pre-registration to sustainability, encompassing critical components such as national immunization technical advisory groups (NITAGs), health technology assessments, resource evaluations, and decision making. This investigation utilizes a multi-phase approach. Initial desk research aimed to collect accumulated evidence about each step of the vaccine access pathway. This constituted the background for an expert panel discussion (

Identifiants

pubmed: 38543920
pii: vaccines12030286
doi: 10.3390/vaccines12030286
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : INFARMA
ID : NA

Auteurs

Marcin Czech (M)

Department of Pharmacoeconomics, Institute of Mother and Child, 01-211 Warsaw, Poland.
Business School, Warsaw University of Technology, 02-008 Warsaw, Poland.

Ewa Augustynowicz (E)

Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health-National Institute of Hygiene-National Research Institute, 00-791 Warsaw, Poland.

Michał Byliniak (M)

INFARMA, The Employers' Union of Innovative Pharmaceutical Companies, 02-670 Warsaw, Poland.

Teresa Jackowska (T)

Department of Pediatrics, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Mikołaj Konstanty (M)

Silesian Pharmaceutical Chamber, 40-637 Katowice, Poland.
Polish Pharmaceutical Chamber, 02-390 Warsaw, Poland.

Ernest Kuchar (E)

Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, 02-091 Warsaw, Poland.

Agnieszka Mastalerz-Migas (A)

Polish Society of Family Medicine, 51-141 Wrocław, Poland.
Department of Family Medicine, Wrocław Medical University, 50-367 Wrocław, Poland.

Maciej Niewada (M)

Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-091 Warsaw, Poland.

Aneta Nitsch-Osuch (A)

Department of Social Medicine and Public Health, Medical University of Warsaw, 02-091 Warsaw, Poland.

Iwona Paradowska-Stankiewicz (I)

Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health-National Institute of Hygiene-National Research Institute, 00-791 Warsaw, Poland.

Jarosław Pinkas (J)

School of Public Health, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Jakub Szulc (J)

Alab Laboratories, 00-739 Warsaw, Poland.

Jacek Wysocki (J)

Department of Preventive Medicine, Poznań University of Medical Sciences, 60-781 Poznań, Poland.

Classifications MeSH